Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

Name: Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
Published: 2026
License: Public Domain

BioMarin Pharmaceutical · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

genetic-diseases

achondroplasia, ach, bone diseases, developmental dwarfism, bone diseases, genetic diseases, inborn, musculoskeletal diseases, natriuretic peptide, c-type, osteochondrodysplasias, physiological effects of drugs, skeletal dysplasias, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

Related documents